REFERENCES
- Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Advanced Drug Delivery Reviews 1995; 16: 3–19, [CSA]
- Ophthalmic Drug Delivery Systems, A K Mitra. Marcel Dekker, Inc, New York 1993; 60
- Lang J C. Ocular drug-delivery conventional ocular formulations. Adv Drug Deliv 1995; 16: 39–43, [CSA], [CROSSREF]
- Bourlais C L, Acar L, Zia H, et al. Ophthalmic Drug Delivery Systems. Prog Retin Eye Res 1998; 17(1)33–58, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Creech J L, Chauhan A, Radke C J. Dispersive mixing in the posterior tear film under a soft contact lens. IEC Res 2001; 40: 3015–3026, [CSA]
- McNamara N A, Polse K A, Brand R D, et al. Tear mixing under a soft contact lens: effects of lens diameter. Am J Ophthalmol 1999; 127(6)659–665, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Hehl E M, Beck R, Luthard K, Guthoff R. Improved penetration of aminoglycosides and fluoroquinolones into the aqueous humour of patients by means of Acuvue contact lenses. Eur J Clin Pharmacol 1999; 55(4)317–323, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schultz C L, Mint J M. Drug delivery system for antiglaucomatous medication. U.S. Patent No. 6 410 045, 2002, June 25
- Nakada K, Sugiyama A. Process for producing controlled drug-release contact lens, and controlled drug-release contact lens thereby produced. U.S. Patent No. 6 027 745, 2002, February 22
- Hillman J S. Management of acute glaucoma with pilocarpine-soaked hydrophilic lens. Br J Ophthalmol 1974; 58: 674–679, [PUBMED], [INFOTRIEVE], [CSA]
- Ramer R, Gasset A. Ocular penetration of pilocarpine. Ann Ophthalmol 1974; 6: 1325–1327, [PUBMED], [INFOTRIEVE], [CSA]
- Montague R, Wakins R. Pilocarpine dispensation for the soft hydrophilic contact lens. Br J Ophthalmol 1975; 59: 455–458, [CSA]
- Hillman J, Masters J, Broad A. Pilocarpine delivery by hydrophilic lens in the management of acute glaucoma. Trans Ophthalmol Soc UK 1975; 95: 79–84, [PUBMED], [INFOTRIEVE], [CSA]
- Giambattista B, Virno M, Pecori G, et al. Possibility of isoproterenol therapy with soft contact lenses: ocular hypotension without systemic effects. Ann Ophthalmol 1976; 8: 819–829, [CSA]
- Marmion V J, Yardakul S. Pilocarpine administration by contact lens. Trans Ophthal Soc UK 1977; 97: 162–163, [PUBMED], [INFOTRIEVE], [CSA]
- Arthur B W, Hay G J, Wasan S M, Willis W E. Ultra-structural effects of topical timolol on rabbit cornea. Arch Ophthalmol 1983; 10: 1607–1610, [CSA]
- Wilson M C, Shields M B. A comparison of clinical variations of the iridocorneal endothelial syndrome. Arch Ophthalmol 1989; 107: 1465–1468, [PUBMED], [INFOTRIEVE], [CSA]
- Fristrom B. A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Opthalmol Scand 1996; 74: 140–144, [CSA]
- Rosenwald P L. Ocular device. U.S. Patent No. 4 484 922, 1984, November 27
- Schultz C L, Nunez I M, Silor D L, Neil M L. assignee. Contact lens containing a leachable absorbed material. U.S. Patent No. 5 723 131, 1998, March 3
- Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004; 45(7)2342–2346, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lasic D. Novel applications of liposomes. Trends Biotechnol 1998; 16: 307–321, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Liposomes from Biophysics to Therapeutics, M Ostro. Marcel Dekker, Inc, New York 1987
- Fitzgerald P, Hadgraft J, Kreuter J, Wilcon C G. A gamma scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987; 40: 81–84, [CSA], [CROSSREF]
- Lee V HL. Applications of liposomes in ocular drug delivery. Liposomes in Ophthalmology and Dermatology, U Pleyer, K Schmidt, H J Thiel. Hippokrates, Stuggart 1993; 53–59
- Betageri G V, Jenkins S A, Parsons D L. Liposome. Drug Delivery Systems. Technomic Publ. Co, Lancester, PA 1993